{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T19:21:24Z","timestamp":1720639284203},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Medicine Supplements"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1016\/j.amjmed.2004.07.004","type":"journal-article","created":{"date-parts":[[2004,9,24]],"date-time":"2004-09-24T15:56:47Z","timestamp":1096041407000},"page":"16-22","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S1","title":["Overview of newer antimicrobial formulations for overcoming pneumococcal resistance"],"prefix":"10.1016","volume":"117","author":[{"given":"William A","family":"Craig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.amjmed.2004.07.004_BIB1","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1086\/314057","article-title":"Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae","volume":"31","author":"Appelbaum","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/dkg321","article-title":"The Alexander Project 1998\u20132000","volume":"52","author":"Jacobs","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB3","first-page":"68","article-title":"Evidence-based guidelines for treatment of bacterial respiratory tract infections in the era of antibiotic resistance","volume":"14","author":"Jacobs","year":"2001","journal-title":"Manag Care Interface"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.otohns.2003.12.003","article-title":"Antimicrobial treatment guidelines for acute bacterial rhinosinusitis","volume":"130","author":"Anon","year":"2004","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"suppl 3","key":"10.1016\/j.amjmed.2004.07.004_BIB5","first-page":"38","article-title":"Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections","volume":"9","author":"Drusano","year":"1997","journal-title":"J Chemother"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archinte.160.10.1399","article-title":"Management of community-acquired pneumonia in the era of pneumococcal resistance","volume":"160","author":"Heffelfinger","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB7","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1086\/380488","article-title":"Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults","volume":"37","author":"Mandell","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB8","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia","volume":"163","author":"Niederman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB9","series-title":"Principles and Practice of Infectious Diseases","first-page":"253","article-title":"Pharmacokinetics and pharmacodynamics on anti-infective agents","author":"Amsden","year":"2000"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.amjmed.2004.07.004_BIB11","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1201-9712(03)90067-1","article-title":"Achieving bacterial eradication using pharmacokinetic\/pharmacodynamic principles","volume":"7","author":"Dagan","year":"2003","journal-title":"Int J Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.amjmed.2004.07.004_BIB12","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1201-9712(03)90066-X","article-title":"How can we predict bacterial eradication?","volume":"7","author":"Jacobs","year":"2003","journal-title":"Int J Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.amjmed.2004.07.004_BIB13","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1201-9712(03)90068-3","article-title":"Implications for antimicrobial prescribing of strategies based on bacterial eradication","volume":"7","author":"Klugman","year":"2003","journal-title":"Int J Infect Dis"},{"issue":"suppl D","key":"10.1016\/j.amjmed.2004.07.004_BIB14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jac\/31.suppl_D.149","article-title":"Post-antibiotic effects in experimental infection models","volume":"31","author":"Craig","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0149-2918(00)88266-1","article-title":"Expanded activity and utility of the new fluoroquinolones","volume":"21","author":"Blondeau","year":"1999","journal-title":"Clin Ther"},{"issue":"suppl 3","key":"10.1016\/j.amjmed.2004.07.004_BIB16","doi-asserted-by":"crossref","first-page":"19S","DOI":"10.1378\/chest.115.suppl_1.19S","article-title":"Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance","volume":"115","author":"Burgess","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB17","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2165\/00003495-200262120-00006","article-title":"The ketolides","volume":"62","author":"Zhanel","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB18","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.279.2.125","article-title":"Pharmacodynamics of levofloxacin","volume":"279","author":"Preston","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB20","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1128\/AAC.45.10.2793-2797.2001","article-title":"Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections","volume":"45","author":"Ambrose","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0924-8579(02)00022-5","article-title":"Animal model pharmacokinetics and pharmacodynamics","volume":"19","author":"Andes","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB22","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1128\/AAC.42.9.2375","article-title":"In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae","volume":"42","author":"Andes","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0732-8893(96)00162-9","article-title":"Antimicrobial resistance issues of the future","volume":"25","author":"Craig","year":"1996","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins","volume":"22","author":"Craig","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00006454-199603000-00015","article-title":"Pharmacokinetics and pharmacodynamics of antibiotics in otitis media","volume":"15","author":"Craig","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jac\/47.2.129","article-title":"Evidence to support the rationale that bacterial eradication in respiratory tract infections is an important aim of antimicrobial therapy","volume":"47","author":"Dagan","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0732-8893(97)00022-9","article-title":"The future\u2014can we learn from the past?","volume":"27","author":"Craig","year":"1997","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB29","unstructured":"Biaxin XL [prescribing information]. North Chicago, IL: Abbott Laboratories; August 2001"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB30","unstructured":"Ceclor CD [prescribing information]. Indianapolis, IN: Eli Lilly Pharmaceuticals; September 1999"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB31","unstructured":"Augmentin XR [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2003"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB32","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0149-2918(01)80061-8","article-title":"The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin\/clavulanate","volume":"23","author":"Kaye","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB33","unstructured":"Berry V, Singley C, Satterfield J, Woodnutt G. Efficacy of a pharmacokinetically enhanced formulation of amoxicillin\/clavulanate against experimental respiratory tract infection (RTI) in rats caused by Streptococcus pneumoniae (Sp). Poster presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 22\u201325, 2001; Chicago, IL"},{"issue":"suppl 2","key":"10.1016\/j.amjmed.2004.07.004_BIB34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1470-9465.2004.00865.x","article-title":"Proof of concept","volume":"10","author":"Craig","year":"2004","journal-title":"Clin Microb Infect"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0924-8579(02)00130-9","article-title":"Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin\/clavulanate","volume":"4","author":"File","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB36","unstructured":"Augmentin ES-600 [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2003"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/AAC.43.1.35","article-title":"Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae","volume":"43","author":"Woodnutt","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB38","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/00006454-200109000-00002","article-title":"Bacteriologic and clinical efficacy of high dose amoxicillin\/clavulanate in children with acute otitis media","volume":"20","author":"Dagan","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.amjmed.2004.07.004_BIB39","unstructured":"Hoberman A, Dagan R, Rosenblut A, et al. Extra-strength amoxicillin\/clavulanate (A\/C-ES) vs azithromycin (AZI) for acute otitis media (AOM) in children. Poster presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14\u201317, 2003; Chicago, IL"}],"container-title":["The American Journal of Medicine Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548276604000044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548276604000044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T05:51:12Z","timestamp":1585893072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548276604000044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S1548276604000044"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2004.07.004","relation":{},"ISSN":["1548-2766"],"issn-type":[{"value":"1548-2766","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}